Article Text

Download PDFPDF
073 Fenfluramine exhibits disease-modifying effects in a mouse model of Dravet syndrome
  1. Thaddeus Reeder1,
  2. John Cha1,
  3. Gregory Filatov1,
  4. Steve Smith2,
  5. Darren Wong1,
  6. Arnold Gammaitoni1
  1. 1Zogenix Inc
  2. 2GemPharma Tech

Abstract

Rationale Fenfluramine (FFA) provides clinically significant reductions in convulsive seizure frequency and improved executive function in patients with Dravet syndrome (DS). FFA also reduces sudden unexpected death in epilepsy (SUDEP) in mouse models of DS. We investigated FFA effects upon survival, myelination, and neuroinflammation in a mouse model of DS.

Methods scn1a+/- mice (DS mice) were treated subcutaneously with FFA. FFPE sagittal brain sections were immunostained with D-MBP antibody for degenerated myelin and CD11b antibody for inflamma- tory microglia.

Results In animals receiving FFA, the mortality rate was reduced to 24% (P< 0.01; Figure 1). Degenerated myelin was enriched in DS mouse cortex and hippocampus compared to wild-type controls. FFA treatment reduced degenerated myelin.

Conclusion This is the first report of increased survival and reductions in myelin degeneration and neuro- inflammation in DS mice treated with FFA. Improved survival and reduced myelin damage and neuroin- flammation demonstrates the claim that FFA exhibits disease-modifying effects in animal models of DS.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.